
Sinopharm Group Co. Ltd.
Sinopharm
Sinopharm Group represents Asia's most formidable pharmaceutical supply chain and manufacturing complex, generating RMB 575.2 billion ($81.3 billion) in FY2025 revenue to rank as the world's second-largest biomedical enterprise by sales volume. Unlike Western innovation-centric competitors, Sinopharm's power derives from an unrivaled vertically integrated ecosystem: a distribution network penetrating virtually 100% of China's hospital and retail pharmacy system, large-scale industrial manufacturing clusters producing chemical generics, traditional Chinese medicines, vaccines, and blood products, and a retail footprint exceeding 10,000 pharmacies. The company's vaccine and biologics cold-chain logistics network—recognized as a national supply chain innovation demonstrator—represents a strategic asset of national security significance. While healthcare cost containment policies (Volume-Based Procurement, NRDL negotiations) compressed traditional drug distribution margins by 3.52% in 2025, Sinopharm's medical device distribution and retail pharmacy segments delivered compensatory growth that sustained its immense revenue scale.
Strengths: An infrastructure advantage that is effectively impossible to replicate—Sinopharm controls China's densest medical logistics network with industry-leading cold-chain capabilities essential for mRNA vaccines, biologics, and blood products, serving as the backbone of the world's second-largest pharmaceutical market. The company's full-spectrum manufacturing—from APIs to finished dosage forms, from chemical drugs to cutting-edge biologics—combined with state-backed strategic positioning, creates a competitive fortress in the Asia-Pacific region that no Western multinational can breach organically.
Weaknesses: Heavy exposure to China's aggressive drug pricing reform agenda—the 2025 VBP and NRDL cycles caused a 3.52% distribution revenue contraction, with further rounds threatening to systematically erode the generics business model. Near-total geographic concentration in China creates single-country risk despite export activities in ~40 nations. The distribution-heavy business mix (lower-margin than innovative pharma) limits overall profitability, while Western brand recognition remains minimal outside professional procurement circles.Read MoreShow Less
Strengths: An infrastructure advantage that is effectively impossible to replicate—Sinopharm controls China's densest medical logistics network with industry-leading cold-chain capabilities essential for mRNA vaccines, biologics, and blood products, serving as the backbone of the world's second-largest pharmaceutical market. The company's full-spectrum manufacturing—from APIs to finished dosage forms, from chemical drugs to cutting-edge biologics—combined with state-backed strategic positioning, creates a competitive fortress in the Asia-Pacific region that no Western multinational can breach organically.
Weaknesses: Heavy exposure to China's aggressive drug pricing reform agenda—the 2025 VBP and NRDL cycles caused a 3.52% distribution revenue contraction, with further rounds threatening to systematically erode the generics business model. Near-total geographic concentration in China creates single-country risk despite export activities in ~40 nations. The distribution-heavy business mix (lower-margin than innovative pharma) limits overall profitability, while Western brand recognition remains minimal outside professional procurement circles.
Listed market data
01099 · HKEX · weeklyHistory →- Market cap
- $6.2 B
- Share price
- HKD 16.98
- 1Y change
- -18.7%
- Recent change
- +0.5%
- Since first close
- -8.3%
- Revenue (TTM)
- $81,310M
11-18 → 11-19
from 2009-09
Financial history
Full market history- 2026-11HKD 16.98≈ $6.2 B+4.9%
- 2026-10HKD 16.19≈ $6 B+9.0%
- 2026-09HKD 14.86≈ $5.5 B-4.1%
- 2026-08HKD 15.50≈ $5.7 B-10.8%
- 2026-07HKD 17.38≈ $6.4 B+9.2%
- 2026-06HKD 15.91≈ $5.9 B-6.0%
- 2026-05HKD 16.92≈ $6.2 B-8.4%
- 2026-04HKD 18.47≈ $6.8 B-8.6%
- 2026-03HKD 20.20≈ $7.4 B-4.4%
- 2026-02HKD 21.14≈ $7.8 B+1.2%
- 2026-01HKD 20.88≈ $7.7 B+7.5%
- 2025-12HKD 19.43≈ $7.2 B—
Ownership & Control
Latest available filings- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines- Sinopharm revenue falls 1.13 percent: Sinopharm stock trades at 5.81 times earnings - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Medical products distributor Sinopharm Group's prelim 9-month revenue slips - TradingViewwww.tradingview.com2026-10-20
- Sinopharm Group Co. Ltd. (SHTDF) Stock Historical Prices & Data - Yahoo! Finance Canadaca.finance.yahoo.com2026-10-19
- Sinopharm Group Stock Rallies 2.2% in Hong Kong - Moomoowww.moomoo.com2026-10-13
- Sinopharm Group Co. Ltd. Research & Ratings | 1099 - Barron'swww.barrons.com2026-10-10
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Listing
SEHK: 01099Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Johnson & Johnson (J&J)· $653 B
- Allergan Aesthetics· $508 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $381 B
- Merck Animal Health· $330 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website SEHK: 01099 , Sinopharm Group 2025 Annual Report
Sinopharm 2025 Interim Report
Forbes — Sinopharm Group Profile
